Proton SBRT for medically inoperable stage i NSCLC

Kenneth D. Westover, Joao Seco, Judith A. Adams, Michael Lanuti, Noah C. Choi, Martijn Engelsman, Henning Willers

Research output: Contribution to journalArticle

36 Citations (Scopus)

Abstract

Introduction: The physical properties of proton beam radiation may offer advantages for treating patients with non-small-cell lung cancer (NSCLC). However, its utility for the treatment of medically inoperable stage I NSCLC patients with stereotactic body radiation therapy (SBRT) is unknown. METHODS: Outcomes for patients with medically inoperable stage I NSCLC treated with proton SBRT were retrospectively analyzed. Proton SBRT was selected as the treatment modality based on pulmonary comorbidities (n = 5), prior chest radiation or/and multiple primary tumors (n = 7), or other reasons (n = 3). Treatments were administered using 2 to 3 proton beams. Treatment toxicity was scored according to common toxicity criteria for adverse events version 4 criteria. RESULTS: Fifteen consecutive patients and 20 tumors were treated with proton SBRT to 42 to 50 Gy(relative biological effectiveness) in 3 to 5 fractions between July 2008 and September 2010. Treatments were well tolerated with only one case of grade 2 fatigue, one case of grade 2 dermatitis, three cases of rib fracture (maximum grade 2), and one case of grade 3 pneumonitis in a patient with severe chronic obstructive pulmonary disease. With a median follow-up of 24.1 months, 2-year overall survival and local control rates were 64% (95% confidence limits, 34%-83%) and 100% (83%-100%), respectively. CONCLUSIONS: We conclude that proton SBRT is effective and well tolerated in this unfavorable group of patients. Prospective clinical trials testing the utility of proton SBRT in stage I NSCLC are warranted.

Original languageEnglish (US)
Pages (from-to)1021-1025
Number of pages5
JournalJournal of Thoracic Oncology
Volume7
Issue number6
DOIs
StatePublished - Jun 2012

Fingerprint

Non-Small Cell Lung Carcinoma
Protons
Radiotherapy
Relative Biological Effectiveness
Radiation
Rib Fractures
Therapeutics
Dermatitis
Chronic Obstructive Pulmonary Disease
Fatigue
Comorbidity
Neoplasms
Pneumonia
Thorax
Clinical Trials
Lung
Survival

Keywords

  • Non-small-cell lung cancer
  • Proton therapy
  • Stereotactic body radiation therapy

ASJC Scopus subject areas

  • Oncology
  • Pulmonary and Respiratory Medicine

Cite this

Westover, K. D., Seco, J., Adams, J. A., Lanuti, M., Choi, N. C., Engelsman, M., & Willers, H. (2012). Proton SBRT for medically inoperable stage i NSCLC. Journal of Thoracic Oncology, 7(6), 1021-1025. https://doi.org/10.1097/JTO.0b013e31824de0bf

Proton SBRT for medically inoperable stage i NSCLC. / Westover, Kenneth D.; Seco, Joao; Adams, Judith A.; Lanuti, Michael; Choi, Noah C.; Engelsman, Martijn; Willers, Henning.

In: Journal of Thoracic Oncology, Vol. 7, No. 6, 06.2012, p. 1021-1025.

Research output: Contribution to journalArticle

Westover, KD, Seco, J, Adams, JA, Lanuti, M, Choi, NC, Engelsman, M & Willers, H 2012, 'Proton SBRT for medically inoperable stage i NSCLC', Journal of Thoracic Oncology, vol. 7, no. 6, pp. 1021-1025. https://doi.org/10.1097/JTO.0b013e31824de0bf
Westover, Kenneth D. ; Seco, Joao ; Adams, Judith A. ; Lanuti, Michael ; Choi, Noah C. ; Engelsman, Martijn ; Willers, Henning. / Proton SBRT for medically inoperable stage i NSCLC. In: Journal of Thoracic Oncology. 2012 ; Vol. 7, No. 6. pp. 1021-1025.
@article{078e05975c0644ddadc9dc76b715e215,
title = "Proton SBRT for medically inoperable stage i NSCLC",
abstract = "Introduction: The physical properties of proton beam radiation may offer advantages for treating patients with non-small-cell lung cancer (NSCLC). However, its utility for the treatment of medically inoperable stage I NSCLC patients with stereotactic body radiation therapy (SBRT) is unknown. METHODS: Outcomes for patients with medically inoperable stage I NSCLC treated with proton SBRT were retrospectively analyzed. Proton SBRT was selected as the treatment modality based on pulmonary comorbidities (n = 5), prior chest radiation or/and multiple primary tumors (n = 7), or other reasons (n = 3). Treatments were administered using 2 to 3 proton beams. Treatment toxicity was scored according to common toxicity criteria for adverse events version 4 criteria. RESULTS: Fifteen consecutive patients and 20 tumors were treated with proton SBRT to 42 to 50 Gy(relative biological effectiveness) in 3 to 5 fractions between July 2008 and September 2010. Treatments were well tolerated with only one case of grade 2 fatigue, one case of grade 2 dermatitis, three cases of rib fracture (maximum grade 2), and one case of grade 3 pneumonitis in a patient with severe chronic obstructive pulmonary disease. With a median follow-up of 24.1 months, 2-year overall survival and local control rates were 64{\%} (95{\%} confidence limits, 34{\%}-83{\%}) and 100{\%} (83{\%}-100{\%}), respectively. CONCLUSIONS: We conclude that proton SBRT is effective and well tolerated in this unfavorable group of patients. Prospective clinical trials testing the utility of proton SBRT in stage I NSCLC are warranted.",
keywords = "Non-small-cell lung cancer, Proton therapy, Stereotactic body radiation therapy",
author = "Westover, {Kenneth D.} and Joao Seco and Adams, {Judith A.} and Michael Lanuti and Choi, {Noah C.} and Martijn Engelsman and Henning Willers",
year = "2012",
month = "6",
doi = "10.1097/JTO.0b013e31824de0bf",
language = "English (US)",
volume = "7",
pages = "1021--1025",
journal = "Journal of Thoracic Oncology",
issn = "1556-0864",
publisher = "International Association for the Study of Lung Cancer",
number = "6",

}

TY - JOUR

T1 - Proton SBRT for medically inoperable stage i NSCLC

AU - Westover, Kenneth D.

AU - Seco, Joao

AU - Adams, Judith A.

AU - Lanuti, Michael

AU - Choi, Noah C.

AU - Engelsman, Martijn

AU - Willers, Henning

PY - 2012/6

Y1 - 2012/6

N2 - Introduction: The physical properties of proton beam radiation may offer advantages for treating patients with non-small-cell lung cancer (NSCLC). However, its utility for the treatment of medically inoperable stage I NSCLC patients with stereotactic body radiation therapy (SBRT) is unknown. METHODS: Outcomes for patients with medically inoperable stage I NSCLC treated with proton SBRT were retrospectively analyzed. Proton SBRT was selected as the treatment modality based on pulmonary comorbidities (n = 5), prior chest radiation or/and multiple primary tumors (n = 7), or other reasons (n = 3). Treatments were administered using 2 to 3 proton beams. Treatment toxicity was scored according to common toxicity criteria for adverse events version 4 criteria. RESULTS: Fifteen consecutive patients and 20 tumors were treated with proton SBRT to 42 to 50 Gy(relative biological effectiveness) in 3 to 5 fractions between July 2008 and September 2010. Treatments were well tolerated with only one case of grade 2 fatigue, one case of grade 2 dermatitis, three cases of rib fracture (maximum grade 2), and one case of grade 3 pneumonitis in a patient with severe chronic obstructive pulmonary disease. With a median follow-up of 24.1 months, 2-year overall survival and local control rates were 64% (95% confidence limits, 34%-83%) and 100% (83%-100%), respectively. CONCLUSIONS: We conclude that proton SBRT is effective and well tolerated in this unfavorable group of patients. Prospective clinical trials testing the utility of proton SBRT in stage I NSCLC are warranted.

AB - Introduction: The physical properties of proton beam radiation may offer advantages for treating patients with non-small-cell lung cancer (NSCLC). However, its utility for the treatment of medically inoperable stage I NSCLC patients with stereotactic body radiation therapy (SBRT) is unknown. METHODS: Outcomes for patients with medically inoperable stage I NSCLC treated with proton SBRT were retrospectively analyzed. Proton SBRT was selected as the treatment modality based on pulmonary comorbidities (n = 5), prior chest radiation or/and multiple primary tumors (n = 7), or other reasons (n = 3). Treatments were administered using 2 to 3 proton beams. Treatment toxicity was scored according to common toxicity criteria for adverse events version 4 criteria. RESULTS: Fifteen consecutive patients and 20 tumors were treated with proton SBRT to 42 to 50 Gy(relative biological effectiveness) in 3 to 5 fractions between July 2008 and September 2010. Treatments were well tolerated with only one case of grade 2 fatigue, one case of grade 2 dermatitis, three cases of rib fracture (maximum grade 2), and one case of grade 3 pneumonitis in a patient with severe chronic obstructive pulmonary disease. With a median follow-up of 24.1 months, 2-year overall survival and local control rates were 64% (95% confidence limits, 34%-83%) and 100% (83%-100%), respectively. CONCLUSIONS: We conclude that proton SBRT is effective and well tolerated in this unfavorable group of patients. Prospective clinical trials testing the utility of proton SBRT in stage I NSCLC are warranted.

KW - Non-small-cell lung cancer

KW - Proton therapy

KW - Stereotactic body radiation therapy

UR - http://www.scopus.com/inward/record.url?scp=84861338223&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84861338223&partnerID=8YFLogxK

U2 - 10.1097/JTO.0b013e31824de0bf

DO - 10.1097/JTO.0b013e31824de0bf

M3 - Article

C2 - 22551902

AN - SCOPUS:84861338223

VL - 7

SP - 1021

EP - 1025

JO - Journal of Thoracic Oncology

JF - Journal of Thoracic Oncology

SN - 1556-0864

IS - 6

ER -